Enlivex Therapeutics (NASDAQ:ENLV) Raised to Strong-Buy at EF Hutton Acquisition Co. I

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by research analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks.com reports.

Separately, HC Wainwright reduced their price objective on shares of Enlivex Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 11th.

Enlivex Therapeutics Price Performance

NASDAQ:ENLV opened at $1.25 on Tuesday. The business has a 50 day simple moving average of $1.33 and a 200 day simple moving average of $2.08. The firm has a market capitalization of $26.09 million, a P/E ratio of -0.90 and a beta of 0.98. Enlivex Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Friday, June 14th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Research analysts anticipate that Enlivex Therapeutics will post -0.81 EPS for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned approximately 0.12% of Enlivex Therapeutics at the end of the most recent quarter. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.